Alliance for Pandemic Preparedness

November 24, 2020

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia

Category:

Topic:

Keywords (Tags):

A randomized placebo-controlled trial of convalescent plasma (CP) infusion for patients with severe COVID-19 (n=228) found no significant difference between the treatment and placebo groups in the improvement in clinical status measured at 30 days using an ordinal scale (OR=0.83, 95%CI 0.52 – 1.35). Overall mortality was 11% in the CP group and 11.4% in the placebo group. Adverse events were similar in the two groups. The infused CP had a median titer of 1:3200 of total SARS-CoV-2 antibodies.

Simonovich et al. (Nov 24, 2020). A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2031304